T2 Translational Research on Aging: Small Business Innovation Awards (R43/R44 Clinical Trial Optional)

Funder: National Institutes of Health

Due Date: 9/5/2019

Budget: Negotiable

Opportunity: PAR-18-184


The involvement of small businesses in translational aging research could hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults.  Therefore, this funding opportunity announcement (FOA) is intended to support innovative research conducted by small businesses through the SBIR program to advance the availability of novel devices, products, health care practices and programs with the potential for commercial success and the likelihood to benefit the lives of older adults.

For the purposes of this FOA, T2 translational research on aging involves the development or evaluation of methods for disseminating (1) results from clinical studies into everyday clinical practice and health decision-making in geriatric medicine (e.g., adapting an efficacious intervention for application in clinical practice and in the community), (2) results from large scale behavioral and community interventions into practice in community organizations, workplaces, and public institutions, and (3) development of new technologies for enhancing research productivity in aging research.  Research activities related to T2 translational research could include data-mining for developing new educational materials, or to inform new health care practices in geriatric medicine and community programs for older adults.

Leave a Reply